Home › Companies › Kymera Therapeutics, Inc. › 2025-2026

Kymera Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Kymera Therapeutics, Inc.’s Form 8-K, filed 2026-06-24 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
277Asset managers
2,441Fund votes
2026-06-24Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Kymera Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Kymera Therapeutics, Inc.

These tallies are Kymera Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-24 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Kymera Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-24
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Bruce Booth, D.Phil.	71,962,459	--	--	5,430,527	1,707,176	Majority: yes
Elect Director: Nello Mainolfi, Ph.D.	73,411,316	--	--	3,981,670	1,707,176	Majority: yes
Elect Director: John Maraganore, Ph.D.	72,501,958	--	--	4,891,028	1,707,176	Majority: yes
Elect Director: Elena Ridloff, CFA	72,453,404	--	--	4,939,582	1,707,176	Majority: yes
Proposal 2: Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers	74,903,687	2,462,732	26,567	--	1,707,176	Majority: yes
Proposal 3: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal yea	79,043,801	38,128	18,233	--	0	Majority: yes

Source: Kymera Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-24 — read the filing on EDGAR.

How asset managers voted at the Kymera Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 277 asset managers that disclosed a Kymera Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Kymera Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers; and

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 74,903,687AGAINST: 2,462,732

Kymera Therapeutics, Inc.’s own tally for this item (“Proposal 2: Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executi”): 74,903,687 for, 2,462,732 against, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,257,588 outstanding shares: 91% for, 3% against (94% of the company cast a for/against vote).

The 276 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 96%

FOR: 96.2%AGAINST: 3.8%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers; and” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	20,917,917	0	For
T. Rowe Price	18,958,195	0	For
Vanguard	8,682,175	1	For
BAKER BROS. ADVISORS LP	8,657,242	0	For
BVF INC/IL	5,502,710	0	For
Atlas Venture Life Science Advisors, LLC	4,411,361	0	For
Wellington	3,421,111	0	For
Avoro Capital Advisors LLC	3,398,093	0	For
Siren, L.L.C.	2,986,830	0	For
BlackRock	2,968,395	8,838	For
GEODE CAPITAL MANAGEMENT, LLC	1,575,171	0	For
Capital Group	0	1,490,604	Against
Capital Research Global Investors	0	1,490,604	Against
AllianceBernstein	1,103,299	0	For
Federated Hermes	1,073,360	0	For
Charles Schwab	996,644	0	For
State Street	820,498	84	For
MUTUAL FUND SERIES TRUST	628,811	0	For
Putnam	585,433	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	565,103	0	For
Jackson National	561,911	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	561,170	0	For
Rock Springs Capital Management LP	468,500	0	For
PICTET ASSET MANAGEMENT SA	437,897	0	For
Polar Capital Holdings Plc	407,050	0	For

Showing the 25 largest of 276 asset managers. See all 276 in the interactive database.

2. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 79,043,801AGAINST: 38,128

Kymera Therapeutics, Inc.’s own tally for this item (“Proposal 3: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered p”): 79,043,801 for, 38,128 against, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,257,588 outstanding shares: 96% for, 0.1% against (96% of the company cast a for/against vote).

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (34,206,713 for, 6 against).

FOR 99.9%

FOR: 34,206,713 (99.9%)AGAINST: 6 (0.0%)ABSTAIN: 17,732 (0.1%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	9,386,510	0	For
Vanguard	8,165,526	0	For
T. Rowe Price	7,712,301	0	For
Capital Group	1,490,604	0	For
BlackRock	1,277,036	0	For
MUTUAL FUND SERIES TRUST	628,811	0	For
Jackson National	561,911	0	For
Federated Hermes	536,680	0	For
Charles Schwab	496,084	0	For
AllianceBernstein	274,851	0	For
Putnam	235,642	0	For
Prudential/PGIM	234,009	0	For
Dimensional	228,222	0	For
State Street	219,191	6	For
Equitable	218,570	0	For
Hartford	210,901	0	For
MFS	204,255	0	For
AB DISCOVERY GROWTH FUND, INC.	186,016	0	For
Voya	173,983	0	For
DRIEHAUS MUTUAL FUNDS	170,127	0	For
Bridge Builder Trust	128,948	0	For
TIAA	118,801	0	For
Lincoln Financial	111,638	0	For
PENN SERIES FUNDS INC	100,500	0	For
Victory Capital	99,631	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

3. To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 71,962,459WITHHELD: 5,430,527

Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: Bruce Booth, D.Phil.”): 71,962,459 for, 5,430,527 withheld, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,257,588 outstanding shares: 87% for, 7% withheld (94% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (32,642,289 for, 0 against).

FOR 95%

FOR: 32,642,289 (95.5%)ABSTAIN: 1,554,640 (4.5%)

Largest asset managers voting on “To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Sh” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,386,510	0	For
Vanguard	8,165,517	9	For
T. Rowe Price	7,712,301	0	For
Capital Group	1,490,604	0	For
BlackRock	1,277,036	0	For
MUTUAL FUND SERIES TRUST	623,469	5,342	For
Jackson National	488,082	73,829	For
Federated Hermes	536,680	0	For
Charles Schwab	496,084	0	For
AllianceBernstein	274,851	0	For
Prudential/PGIM	222,115	11,894	For
Dimensional	0	228,222	Abstain
Putnam	226,602	0	For
State Street	440	218,757	Abstain
Equitable	218,570	0	For
Hartford	210,901	0	For
MFS	0	204,255	Abstain
AB DISCOVERY GROWTH FUND, INC.	186,016	0	For
Voya	173,983	0	For
DRIEHAUS MUTUAL FUNDS	0	170,127	Abstain
Bridge Builder Trust	10,910	118,038	Abstain
TIAA	118,801	0	For
Lincoln Financial	46,281	65,357	Abstain
PENN SERIES FUNDS INC	99,000	1,500	For
Victory Capital	509	99,122	Abstain

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

4. To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 72,453,404WITHHELD: 4,939,582

Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: Elena Ridloff, CFA”): 72,453,404 for, 4,939,582 withheld, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,257,588 outstanding shares: 88% for, 6% withheld (94% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (32,290,958 for, 0 against).

FOR 94%

FOR: 32,290,958 (94.4%)ABSTAIN: 1,905,971 (5.6%)

Largest asset managers voting on “To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Sh” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,386,510	0	For
Vanguard	8,162,065	3,461	For
T. Rowe Price	7,712,301	0	For
Capital Group	1,490,604	0	For
BlackRock	1,277,036	0	For
MUTUAL FUND SERIES TRUST	623,469	5,342	For
Jackson National	488,082	73,829	For
Federated Hermes	536,680	0	For
Charles Schwab	496,084	0	For
AllianceBernstein	0	274,851	Abstain
Prudential/PGIM	222,115	11,894	For
Dimensional	0	228,222	Abstain
Putnam	226,602	0	For
State Street	218,939	258	For
Equitable	102,594	115,976	Abstain
Hartford	210,901	0	For
MFS	0	204,255	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	186,016	Abstain
Voya	173,983	0	For
DRIEHAUS MUTUAL FUNDS	0	170,127	Abstain
Bridge Builder Trust	10,910	118,038	Abstain
TIAA	118,801	0	For
Lincoln Financial	84,281	27,357	For
PENN SERIES FUNDS INC	100,500	0	For
Victory Capital	509	99,122	Abstain

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

5. To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Maraganore, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 72,501,958WITHHELD: 4,891,028

Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: John Maraganore, Ph.D.”): 72,501,958 for, 4,891,028 withheld, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,257,588 outstanding shares: 88% for, 6% withheld (94% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (32,399,023 for, 0 against).

FOR 95%

FOR: 32,399,023 (94.7%)ABSTAIN: 1,797,906 (5.3%)

Largest asset managers voting on “To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Sh” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,386,510	0	For
Vanguard	8,165,518	8	For
T. Rowe Price	7,712,301	0	For
Capital Group	1,490,604	0	For
BlackRock	1,277,036	0	For
MUTUAL FUND SERIES TRUST	623,469	5,342	For
Jackson National	488,082	73,829	For
Federated Hermes	0	536,680	Abstain
Charles Schwab	496,084	0	For
AllianceBernstein	274,851	0	For
Prudential/PGIM	222,115	11,894	For
Dimensional	0	228,222	Abstain
Putnam	226,602	0	For
State Street	218,939	258	For
Equitable	218,570	0	For
Hartford	210,901	0	For
MFS	0	204,255	Abstain
AB DISCOVERY GROWTH FUND, INC.	186,016	0	For
Voya	173,983	0	For
DRIEHAUS MUTUAL FUNDS	0	170,127	Abstain
Bridge Builder Trust	10,910	118,038	Abstain
TIAA	118,801	0	For
Lincoln Financial	84,281	27,357	For
PENN SERIES FUNDS INC	100,500	0	For
Victory Capital	509	99,122	Abstain

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

6. To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Nello Mainolfi, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 73,411,316WITHHELD: 3,981,670

Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: Nello Mainolfi, Ph.D.”): 73,411,316 for, 3,981,670 withheld, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,257,588 outstanding shares: 89% for, 5% withheld (94% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (32,965,976 for, 0 against).

FOR 96%

FOR: 32,965,976 (96.4%)ABSTAIN: 1,230,953 (3.6%)

Largest asset managers voting on “To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Sh” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,386,510	0	For
Vanguard	8,165,519	7	For
T. Rowe Price	7,712,301	0	For
Capital Group	1,490,604	0	For
BlackRock	1,277,036	0	For
MUTUAL FUND SERIES TRUST	623,469	5,342	For
Jackson National	488,082	73,829	For
Federated Hermes	536,680	0	For
Charles Schwab	496,084	0	For
AllianceBernstein	274,851	0	For
Prudential/PGIM	222,115	11,894	For
Dimensional	0	228,222	Abstain
Putnam	226,602	0	For
State Street	218,939	258	For
Equitable	218,570	0	For
Hartford	210,901	0	For
MFS	204,255	0	For
AB DISCOVERY GROWTH FUND, INC.	186,016	0	For
Voya	0	173,983	Abstain
DRIEHAUS MUTUAL FUNDS	0	170,127	Abstain
Bridge Builder Trust	10,910	118,038	Abstain
TIAA	118,801	0	For
Lincoln Financial	84,281	27,357	For
PENN SERIES FUNDS INC	100,500	0	For
Victory Capital	509	99,122	Abstain

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

7. To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (27,523 for, 0 against).

FOR: 27,523 (100.0%)

Largest asset managers voting on “To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Sh” at Kymera Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Advisors' Inner Circle Fund III	9,443	For
Franklin Alternative Strategies Funds	9,040	For
Putnam	9,040	For

Largest Kymera Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Kymera Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 82,257,588 shares outstanding at the time of that meeting.

Top Kymera Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	25.43%
2	T. Rowe Price	23.05%
3	Vanguard	10.55%
4	BAKER BROS. ADVISORS LP	10.52%
5	BVF INC/IL	6.69%
6	Atlas Venture Life Science Advisors, LLC	5.36%
7	Wellington	4.16%
8	Avoro Capital Advisors LLC	4.13%
9	Siren, L.L.C.	3.63%
10	BlackRock	3.62%

Reported Kymera Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Kymera Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.22%	13F
FMR LLC	10.85%	DEF14A
Entities affiliated with Baker Bros. Advisors LP	10.55%	DEF14A
Felix J. Baker, Ph.D.	10.55%	DEF14A
Avoro Capital Advisors LLC	9.42%	DEF14A
Entities affiliated with BVF Partners L.P.	8.47%	DEF14A
Vanguard Group	7.62%	13F
T. Rowe Price	7.37%	13F
BVF PARTNERS L P/IL	6.37%	13D
Entities affiliated with the Vanguard Group	6.36%	DEF14A

Percentages above are of 82,257,588 shares outstanding, as reported by Kymera Therapeutics, Inc. on its Form 10-Q dated 2026-04-24 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Kymera Therapeutics, Inc.’s 10-Q dated 2026-04-24. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Kymera Therapeutics, Inc.'s shareholder meeting held 2026-06-24, in the 2025-2026 proxy season, 277 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,441 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Kymera Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-24.

Kymera Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).